European Hematology Association Congress | Conference

Saad Z. Usmani, MD, MBA, FACP, Talks About Durable and Deep Responses of Cilta-Cel for Patients With Multiple Myeloma
June 16, 2021

Usmani noted the strong overall response and stringent complete response rates observed with ciltacabtagene autoleucel for multiple myeloma at a median follow-up of 18 months.

Data Collected in Patients With DLBCL Reveal Real-World Trends for Use of Axi-Cel and Tisa-Cel
June 16, 2021

Real-world data regarding the use of tisagenlecleucel and axicabtagene ciloleucel CAR T-cell therapy are reported at 2021 EHA.

Daratumumab Plus CyBorD Followed by Daratumumab Maintenance Achieves Deep Responses for Multiple Myeloma
June 16, 2021

An end-of-study analysis of the LYRA trial found that patients with treatment-naïve and relapsed multiple myeloma achieved durable responses to daratumumab plus CyBorD induction followed by daratumumab maintenance therapy.